Elena Manole

Elena Manole

Auto-generated profile, based on publicly available information

Elena Manole

Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2020 in Research Square
Verified
Preprint
Open access
PDF file
VLVitalie Lisnic
Vitalie Lisnic
VNVictor Nemtan
Victor Nemtan
EHEvghenia Hacina
Evghenia Hacina
GTGalina Topciu
Galina Topciu
EMElena Manole
Elena Manole
RKRüdiger von Kummer
Rüdiger von Kummer
Immunocompromised status keeps on being a challenge for a neurologist, especially in the context of the coronavirus disease – 19 (COVID-19) pandemic. We report a clinical case of a human-immunodeficiency virus (HIV) - positive patient who developed an acute transverse myelitis. Magnetic Resonance Imaging (MRI) examination showed longitudinally extensive spinal cord abnormality, and laboratory tests confirmed SARS-CoV-2 infection. The patient responded to methylprednisolone pulse therapy and therapeutic plasma exchange. No cases of HIV-positive patients with myelitis and COVID-19 has been reported yet.

1 October 2021 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
ECElena Costru-Tasnic
Elena Costru-Tasnic
MGMihail Gavriliuc
Mihail Gavriliuc
EMElena Manole
Elena Manole
Ischemic stroke is one of the leading causes of mortality and disability worldwide. Numerous studies were performed to assess the risk of clinical deterioration of acute ischemic stroke patients, including the risk of haemorrhagic transformation. The complexity of cerebral ischemia pathology raised the possibility of a multitude of candidate-molecules to be studied as stroke biomarkers. The blood brain barrier integrity biomarkers have shown promising results both in fundamental and clinical studies. Matrix metalloproteinases have been extensively analysed and gave encouraging results for predicting unfavourable neurological outcome, including the risk for haemorrhagic transformation. Matrix metalloproteinase-9 plays a crucial role in the disruption of the blood-brain barrier following focal cerebral ischemic stroke. Elevated matrix metalloproteinase-2 levels are responsible for the degradation of tight junction proteins, basal lamina and neuronal injury after ischemia, and may contribute to infarction and hemorrhagic volume. The review provides an overview of matrix metalloproteinases’ role in the prognosis of acute ischemic stroke patients, regarding the stroke outcome and the risk of haemorrhagic transformation. Conclusions: Matrix metalloproteinases, especially gelatinases, are extensively studied for their predictive value in ischemic stroke evolution. Matrix metalloproteinase-2 and matrix metalloproteinase-9 correlate with stroke severity and haemorrhagic transformation in acute ischemic stroke, but large validation studies are needed for practical translation. Future studies should focus on developing a biomarker panel for predicting outcomes in stroke patients.

1 May 2022 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
EMElena Manole
Elena Manole
CTCristina Tiu
Cristina Tiu
AVAleksandras Vilionskis
Aleksandras Vilionskis
ATAlexander Tsiskaridze
Alexander Tsiskaridze
EZEremei Zota
Eremei Zota
SGStanislav Groppa
Stanislav Groppa
Introduction. There were no data on in-hospital stroke care indicators until Moldova’s accession to the international Registry of Stroke Care Quality (RES-Q) platform in 2016. The aim of this paper was to assess the acute stroke care quality in Moldova based on the data of the RES-Q registry. Material and methods. We analyzed the data of all patients with acute ischemic and hemorrhagic stroke of the RES-Q from 15 Moldovan hospitals. Data were collected for one month each year, during a 3-year period (2017-2019). Data analysis was performed between hospitals according to their access to a brain CT facility for Moldovan participating hospitals. Additionally, Moldovan data were compared with other three ESO-EAST (European Stroke Organization Enhancing and Accelerating Stroke Treatment) project countries: Romania, Lithuania, and Georgia. Results. A total of 1660 patients were recruited in the study, mean age of 68 years (49% men). Moldova registered poorer results in number of brain CT performed (81% [95% CI 79-84%]), dysphagia screening (29% [95% CI 27-32%]), IV thrombolysis performed (3% [95% CI 2-4%]), administration of anticoagulants (44% [95% CI 39-49%]) and statins (42% [95% CI 39-45%]) at discharge, in-hospital stroke mortality (17% [95% CI 15- 19%]). Within Moldova the stroke care quality was driven by the access to CT scan. Conclusions. Our study highlighted some serious gaps of in-hospital stroke care performance in Moldova, such as the lack of CT scans in many public hospitals, the absence of a national stroke center network, extremely low accessibility of IV thrombolysis and unsatisfactory implementation of secondary stroke prevention treatment

1 January 2022 in Bulletin of the Academy of Sciences of Moldova. Medical Sciences
Verified
Journal Article
Open access
PDF file
MDMaria Dumanscaia
Maria Dumanscaia
NTNatalia Tibirna
Natalia Tibirna
ADAlexandru Dorobets
Alexandru Dorobets
EMElena Manole
Elena Manole
OOOlesea Odainic
Olesea Odainic
Subarachnoid hemorrhage (SAH) accounts for about 2-7% of all strokes. In 85% cases SAH is caused by an aneurysmal rupture, 10% of SAH are non-aneurysmal, non-traumatic, and 5% of SAH is due to other causes. The risk factors with a major resonance are arterial hypertension and smoking.The purpose of the study was the analysis of the risk factors, clinical course and prognosis in patients with SAH, which was not determined by the rupture of aneurysm or craniocerebral trauma.Methods: The patients were collected during the hospitalization in the Institute of Neurology and Neurosurgery “Diomid Gherman” between 2019 and March 2021. The diagnosis was confirmed by brain CT, CT angiography and cerebral MRI. In this study, for the clinical, paraclinical evaluation and prognostic were used the Hunt-Hess, WFNS, mFisher, mRankin scales.Results: The average age of the 23 research patients is 59,85 years old. Risk factors were assessed: hypertension – 20,smoking – 3, diabetes – 2, obesity – 3, dyslipidemia–2, COVID-19 – 2, autoimmune diseases – 2. The patient’s prognosiswas determined according to the scales (medial score): Hunt-Hess grade 2 (2,39), WFNS grade 1-2 (1,78), mFisher grade1-2 (1,82), mRankin score 1-2 (1,73), 5 patients – developed vasospasm, 2 patients – died.Conclusions: SAH non-aneurysm and non-traumatic, has an almost equal gender distribution, has developed in middle-aged adult, the most common risk factor being arterial hypertension. Compared to women, men with non-anevrismaland non-traumatic SAH presented several associated risk factors, but at the same time they had good clinical results, lowcomplication rates and favorable prognosis.

1 November 2025
Verified
Journal Article
Closed access
DZDiana Zetu-Buciuscan
Diana Zetu-Buciuscan
EMElena Manole
Elena Manole
ECElena Costru-Tasnic
Elena Costru-Tasnic
LRLilia Rotaru
Lilia Rotaru
SOStela Odobescu
Stela Odobescu
OGOxana Grosu
Oxana Grosu
Stroke represents a major public health issue, causing millions of deaths annually and generating a significant burden in terms of disability. The COVID-19 pandemic profoundly influenced the management of patients with acute stroke, leading to reduced hospital admissions and delays in therapeutic procedures. Studies have shown a decrease in thrombolysis and thrombectomy during the early months, as well as prolonged critical intervals such as "onset-to-door" and "door-to-CT," mainly due to epidemiological measures and the mandatory use of protective equipment. In the post-pandemic period, healthcare systems have adapted their protocols, with some being maintained and others discontinued. Recent data indicate improvements in "door-to-needle" times and more efficient clinical workflows. At the same time, the persistence of post-COVID vascular risk complicates patient outcomes, as SARS-CoV-2 infection has been shown to double cardiovascular risk up to three years after the acute episode, with vaccination significantly mitigating these adverse effects. Innovative methods, such as rapid tests for detecting large vessel occlusions and the expansion of telestroke networks, are modernizing therapeutic strategies. The systematic review of literature published between 2020-2025 highlights regional variability in service organization but also demonstrates a clear trend toward improved efficiency in the post-pandemic era. Conclusions emphasize the need to strengthen telemedicine, standardize protocols, and minimize therapeutic delays to optimize outcomes for stroke patients.

1 December 2022 in Bulletin of the Academy of Sciences of Moldova. Medical Sciences
Verified
Journal Article
Open access
PDF file
OGOxana Grosu
Oxana Grosu
GZGalina Zolotco
Galina Zolotco
GCGalina Corcea
Galina Corcea
EMElena Manole
Elena Manole
Transverse myelitis (TM) is a clinical syndrome in which an inflammatory process causes neuronal damage to the spinal cord, leading to varying degrees of muscle weakness, sensory changes, and autonomic dysfunction. MT can be a form of presentation of a multi-focal CNS disease, multi-systemic, infectious, paraneoplastic, demyelinating, autoimmune or idiopathic disease.The purpose of the research was to analyze the cases of transverse myelitis codes in patients treated and hospitalized in the “Diomid Gherman” Institute of Neurology and Neurosurgery.Material and method: 22905 medical records of patients treated in the Institute of Neurology and Neurosurgery between February 2018 and April 2022 were analyzed, 53 patients diagnosed with transverse myelitis were selected and 44 records were eligible, analyzed and included in the study. Results: The average age of the subjects included in the research was 50.9±11.7 years, they were on treatment for an average of 11.2±8.04 days. Neurological manifestations were presented in 43 people. The clinical presentation included: sensitivity disorders (75%), sphincteric disorders (61.4%), limb paresthesia (40.9%), motility disorders (95.5%), fever (4.5%), depression (6.8%), headache (15.9%), back pain (15.9%). The most frequent investigations performed on patients in the study group was CT/MRI thoracic, cervical, lumbo-sacral, cerebral, EMG. Lumbar puncture was performed in 32 patients (72.7%) with CSF examination. Laboratory analyzes showed signs of inflammation - 54.5%, elevated blood sugar - 40.8%, dyslipidemia - 38.6% and anemia - 25%. Corticosteroid treatment was performed in 25 subjects (56.8%) with improvement in most cases (80%). Frequent complications were urinary infection (52.3%), pneumonia (9.1%), 2 deaths (4.5%). Conclusion: The analysis of the institutional cohort of patients with transverse myelitis confirmed that the diagnosis of MT continues to present a challenge and requires a complex approach, correct both clinical and paraclinical.